ReviewFrontiers in microbiology2022
Efficiency of Antimicrobial Peptides Against Multidrug-Resistant Staphylococcal Pathogens.
Review in Frontiers in microbiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 26 citations in OpenAlex.
- The bovine mammosphere-derived epithelial cell secretome inhibits bacterial growth in vitro and contains peptidoglycan recognition protein 1.Veterinary and animal science · 2026Article
- Optimized expression and antimicrobial activity of rainbow trout defensin 3 in Komagataella phaffii.Applied microbiology and biotechnology · 2026Article
- The Evolution of Symbiosis inBiomolecules · 2026Review
- Bacterial warfare at the molecular level:Current research in microbial sciences · 2026Article
- Biomolecule-functionalized dental implant surfaces: Towards augmenting soft tissue integration.Bioactive materials · 2025Review
- Comprehensive Prevention and Control of Mastitis in Dairy Cows: From Etiology to Prevention.Veterinary sciences · 2025Review
- Broad-Spectrum Antimicrobial Efficacy of Cyclic Antimicrobial Peptide Against Multidrug-ResistantACS medicinal chemistry letters · 2025Article
- The Role and Mechanisms of Antimicrobial Peptides in Overcoming Multidrug-Resistant Bacteria.Molecules (Basel, Switzerland) · 2024Review
- Immunomodulation in Non-traditional Therapies for Methicillin-resistant Staphylococcus aureus (MRSA) Management.Current microbiology · 2024Review
- The two-component regulatory systems GraRS and SrrAB mediateApplied and environmental microbiology · 2024Article
- Ursoricin, a bacteriocin ofApplied and environmental microbiology · 2024Article
- Pharmacological composition based on bacteriocinnisin in experimentsOpen veterinary journal · 2024Article
- Basic concepts, recent advances, and future perspectives in the diagnosis of bovine mastitis.Journal of veterinary science · 2024Review
- Effect of Camel Peptide on the Biofilm ofAntibiotics (Basel, Switzerland) · 2023Article
- Oreoch-1: A Peptide fromPathogens (Basel, Switzerland) · 2023Article
- Immunity in Sea Turtles: Review of a Host-Pathogen Arms Race Millions of Years in the Running.Animals : an open access journal from MDPI · 2023Review
- Different CprABC amino acid sequences affect nisin A susceptibility in Clostridioides difficile isolates.PloS one · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antibiotics play a vital role in saving millions of lives from fatal infections; however, the inappropriate use of antibiotics has led to the emergence and propagation of drug resistance worldwide. Multidrug-resistant bacteria represent a significant challenge to treating infections due to the limitation of available antibiotics, necessitating the investigation of alternative treatments for combating these superbugs. Under such circumstances, antimicrobial peptides (AMPs), including human-derived AMPs and bacteria-derived AMPs (so-called bacteriocins), are considered potential therapeutic drugs owing to their high efficacy against infectious bacteria and the poor ability of these microorganisms to develop resistance to them. Several staphylococcal species including
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.